AI-human collaboration in a “Virtual Lab” successfully designs and experimentally validates nanobodies with enhanced binding to SARS-CoV-2 variants, offering a novel approach to interdisciplinary research.
Grail, aiming to market a blood test for cancer, faces host of challenges as it debuts on Nasdaq
On Tuesday, shares of Grail, the liquid biopsy company that hopes that its test, Galleri, will be widely used to screen for cancer, will become
June 24, 2024